|
WO2020141452A1
|
|
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
KR20200143493A
|
|
Use of anti-FAM19A5 antibodies to treat atherosclerosis
|
|
WO2020079595A1
|
|
Use of anti-fam19a5 antibodies
|
|
US2021054062A1
|
|
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
CA3098807A1
|
|
Adeno-associated virus (aav) delivery of anti-fam19a5 antibodies
|
|
CA3097999A1
|
|
Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
|
|
EP3692171A1
|
|
Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment and diagnosis of mood disorders
|
|
EP3645040A1
|
|
Use of anti-fam19a5 antibodies for treating cancers
|
|
US2020157202A1
|
|
Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of glaucoma
|
|
CN111344011A
|
|
Use of anti-FAM 19a5 antibodies for treating fibrosis
|
|
CN111315774A
|
|
anti-FAM 19a5 antibodies and uses thereof
|
|
KR20180061130A
|
|
Spexin-based GALR2 agonists and use thereof
|
|
CA3042989A1
|
|
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
